A Fatal Case of Bictegravir-Induced Fulminant Hepatic Failure
- PMID: 36856947
- DOI: 10.1007/s40261-023-01250-1
A Fatal Case of Bictegravir-Induced Fulminant Hepatic Failure
References
-
- Spagnuolo V, Castagna A, Lazzarin A. Bictegravir. Curr Opin HIV. AIDS. 2018;13:326–33. https://doi.org/10.1097/COH.0000000000000468 . - DOI
-
- Wohl D, Clarke A, Maggiolo F, Garner W, Laouri M, Martin H, et al. Patient-reported symptoms over 48 weeks among participants in randomized, double-blind, phase III non-inferiority trials of adults with HIV on co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus co-formulated abacavir, dolutegravir, and lamivudine. Patient. 2018;11:561–73. https://doi.org/10.1007/s40271-018-0322-8. - DOI - PubMed - PMC
-
- Rolle C-PM, Nguyen V, Patel K, Cruz D, Hinestrosa F, DeJesus E. 1012. Efficacy, safety and tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected virologically-suppressed older adults in a real-world setting. Open Forum Infect Dis. 2020;7:S534–5. doi: https://doi.org/10.1093/OFID/OFAA439.1198 .
-
- Nolan NS, Adamson S, Reeds D, O’Halloran JA: Bictegravir-based antiretroviral therapy-associated accelerated hyperglycemia and diabetes mellitus. Open Forum Infect Diss. 2021;8. doi: https://doi.org/10.1093/OFID/OFAB077
-
- Senneker T, Tseng A. An update on neuropsychiatric adverse effects with second-generation integrase inhibitors and nonnucleoside reverse transcriptase inhibitors. Curr Opin HIV AIDS. 2021;16:309–20. https://doi.org/10.1097/COH.0000000000000705 . - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical